These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

486 related items for PubMed ID: 14747041

  • 21. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.
    Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di'SantAgnese PA, Trump D, Eastern Cooperative Oncology Group study EST 3886.
    Lancet Oncol; 2006 Jun; 7(6):472-9. PubMed ID: 16750497
    [Abstract] [Full Text] [Related]

  • 22. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
    Eastham JA, Kelly WK, Grossfeld GD, Small EJ, Cancer and Leukemia Group B.
    Urology; 2003 Dec 29; 62 Suppl 1():55-62. PubMed ID: 14747042
    [Abstract] [Full Text] [Related]

  • 23. High-risk localized prostate cancer: primary surgery and adjuvant therapy.
    Skinner EC, Glode LM.
    Urol Oncol; 2003 Dec 29; 21(3):219-27. PubMed ID: 12810210
    [Abstract] [Full Text] [Related]

  • 24. Contemporary treatment of high-risk localized prostate cancer.
    Tareen B, Kimmel J, Huang WC.
    Expert Rev Anticancer Ther; 2010 Jul 29; 10(7):1069-76. PubMed ID: 20645696
    [Abstract] [Full Text] [Related]

  • 25. Stage T3 prostate cancer: a nonrandomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy.
    Corn BW, Valicenti RK, Mulholland SG, Hyslop T, Gomella L.
    Urology; 1998 May 29; 51(5):782-7. PubMed ID: 9610592
    [Abstract] [Full Text] [Related]

  • 26. [Postoperative radiotherapy of prostate cancer].
    Guérif S, Latorzeff I, Lagrange JL, Hennequin C, Supiot S, Garcia A, François P, Soulié M, Richaud P, Salomon L.
    Cancer Radiother; 2014 Oct 29; 18(5-6):517-23. PubMed ID: 25195116
    [Abstract] [Full Text] [Related]

  • 27. Endocrine therapy of prostate cancer.
    Bare RL, Torti FM.
    Cancer Treat Res; 1998 Oct 29; 94():69-87. PubMed ID: 9587683
    [Abstract] [Full Text] [Related]

  • 28. Combined androgen blockade: the gold standard for metastatic prostate cancer.
    McLeod DG, Crawford ED, DeAntoni EP.
    Eur Urol; 1997 Oct 29; 32 Suppl 3():70-7. PubMed ID: 9267789
    [Abstract] [Full Text] [Related]

  • 29. [Neoadjuvant hormone therapy before prostatectomy for cancer localized to the prostate].
    Boccon-Gibod L.
    Prog Urol; 1997 Feb 29; 7(1):97-8. PubMed ID: 9116748
    [No Abstract] [Full Text] [Related]

  • 30. Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy?
    Pai HH, Eldridge B, Bishop D, Alexander A, Lesperance M, Blood P, Lim J, Ludgate C.
    Can J Urol; 2009 Apr 29; 16(2):4541-52. PubMed ID: 19364426
    [Abstract] [Full Text] [Related]

  • 31. [Adjuvant treatment after total prostatectomy].
    Richaud P.
    Ann Urol (Paris); 2007 Oct 29; 41 Suppl 3():S69-72. PubMed ID: 18297903
    [Abstract] [Full Text] [Related]

  • 32. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
    Carrie C, Hasbini A, de Laroche G, Richaud P, Guerif S, Latorzeff I, Supiot S, Bosset M, Lagrange JL, Beckendorf V, Lesaunier F, Dubray B, Wagner JP, N'Guyen TD, Suchaud JP, Créhange G, Barbier N, Habibian M, Ferlay C, Fourneret P, Ruffion A, Dussart S.
    Lancet Oncol; 2016 Jun 29; 17(6):747-756. PubMed ID: 27160475
    [Abstract] [Full Text] [Related]

  • 33. [Adjuvant and neoadjuvant drug therapy for prostate cancer].
    Miller K, Lein M, Schostak M, Schrader M.
    Urologe A; 2008 Nov 29; 47(11):1460-4. PubMed ID: 18813902
    [Abstract] [Full Text] [Related]

  • 34. The role of induction androgen deprivation prior to radical prostatectomy.
    Soloway MS, Watson R.
    Eur Urol; 1996 Nov 29; 29 Suppl 2():114-8. PubMed ID: 8717473
    [Abstract] [Full Text] [Related]

  • 35. Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer.
    Hellerstedt B.
    Urology; 2003 Dec 29; 62 Suppl 1():79-86. PubMed ID: 14747045
    [Abstract] [Full Text] [Related]

  • 36. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
    Kroepfl D, Loewen H, Roggenbuck U, Musch M, Klevecka V.
    BJU Int; 2006 May 29; 97(5):985-91. PubMed ID: 16643480
    [Abstract] [Full Text] [Related]

  • 37. [Is maximal androgenic blockade necessary in the treatment of prostatic cancer?].
    Matveev BP, Bukharkin BV.
    Urologiia; 2003 May 29; (6):6-10. PubMed ID: 14708235
    [Abstract] [Full Text] [Related]

  • 38. Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated?
    Scolieri MJ, Altman A, Resnick MI.
    J Urol; 2000 Nov 29; 164(5):1465-72. PubMed ID: 11025684
    [Abstract] [Full Text] [Related]

  • 39. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer.
    Wieder JA, Soloway MS.
    J Urol; 1998 Aug 29; 160(2):299-315. PubMed ID: 9679867
    [Abstract] [Full Text] [Related]

  • 40. Avoidance and management of positive surgical margins before, during and after radical prostatectomy.
    Bott SR, Kirby RS.
    Prostate Cancer Prostatic Dis; 2002 Aug 29; 5(4):252-63. PubMed ID: 12627209
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.